Capecitabine Tablet, Film Coated
Product Images NDC 70756-815

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 70756-815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lifestar Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cape (Capecitabine 01)

Chemical structure of capecitabine, displaying its molecular arrangement with rings, hydroxyl groups, and a fluorine atom, corresponding to the active ingredient capecitabine.*

FDA Label Image

Capecitabine-02 (Capecitabine 02)

An illustration diagram depicting the metabolic pathway of Capecitabine. The diagram shows chemical structures of Capecitabine and its metabolites: 5'-DFCR, 5'-DFUR, and 5-FU, with arrows indicating enzymatic conversions by Carboxylesterase, Cyd deaminase, and dThdPase enzymes.*

FDA Label Image

Figure1 (Figure1)

A survival curve graph comparing survival rates over time between two treatment groups: 5-FU + Leucovorin (dashed line) and Capecitabine (solid line). The x-axis represents months since randomization, and the y-axis shows survival probability from 0.1 to 1.0. The number of subjects at risk is indicated below the x-axis for both groups at various time points up to 96 months.*

FDA Label Image

Figure2 (Figure2)

A survival curve graph comparing two treatment groups over time in months post-randomization. The x-axis represents months since randomization up to 96 months, and the y-axis shows survival probability from 0 to 1. Two lines represent the groups: a dashed line for 5-FU + Leucovorin and a solid line for Capecitabine, showing survival trends. The number of patients at risk is noted below the x-axis for both groups at various time points.*

FDA Label Image

Fig:3 (Figure3new)

A Kaplan-Meier survival curve comparing estimated probability over time (days) between two treatment groups: 5-FU plus Leucovorin (Mayo Regimen) and capecitabine 1250 mg/sqm twice daily. The graph shows survival probability decreasing over approximately 1500 days.*

FDA Label Image

Figure5 (Figure5)

A survival curve chart comparing estimated probability over time (in days) between two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks (solid line). The vertical arrows mark specific time points on the x-axis between 350 and 450 days.*

FDA Label Image

Rev150mg (Newcapecitabine Tablets 150 mg 1200024384 V00)

Capecitabine Tablets USP 150 mg film-coated tablets package label. The label indicates oral route, prescription use only, and a quantity of 60 tablets. It includes storage instructions and manufacturer details for Lifestar Pharma LLC and Reliance Life Sciences Pvt. Ltd.*

FDA Label Image

Rev500mg (Newrevcapecitabine Tablets 500 mg 1200024383 V00)

Label for Capecitabine Tablets, USP 500 mg oral film-coated tablets by Lifestar Pharma LLC. The label indicates 120 tablets per bottle, prescription only. It includes storage instructions, a dosage caution not to crush or cut tablets, and manufacturing details including Reliance Life Sciences Pvt. Ltd., India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.